Figure 1From: Safety and efficacy of a caspofungin-based combination therapy for treatment of proven or probable aspergillosis in pediatric hematological patientsa) No difference was found in the 100-day survival between the patients of group A, who were started on a caspofungin-based combination therapy within < 7 days from diagnosis of IA vs the patients of group B, who were started on a caspofungin-based combination therapy after 7 days from diagnosis of IA. b) and c) Kaplan-Meier estimate of 100-day survival and OS according to the timing of diagnosis of IA: IA after diagnosis of underlying disease vs IA after HSCT vs IA after relapse.Back to article page